Head-To-Head Analysis: Sight Sciences (NASDAQ:SGHT) & Valeritas (OTCMKTS:VLRXQ)

Valeritas (OTCMKTS:VLRXQ) and Sight Sciences (NASDAQ:SGHT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of current recommendations for Valeritas and Sight Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valeritas	0	0	0	0	0.00
Sight Sciences	0	5	0	0	2.00

Sight Sciences has a consensus target price of $6.00, indicating a potential upside of 28.21%. Given Sight Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Sight Sciences is more favorable than Valeritas.

Earnings & Valuation

This table compares Valeritas and Sight Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valeritas	N/A	N/A	N/A	N/A	N/A
Sight Sciences	$79.40 million	2.97	-$55.55 million	($1.07)	-4.37

Valeritas has higher earnings, but lower revenue than Sight Sciences.

Profitability

This table compares Valeritas and Sight Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valeritas	N/A	N/A	N/A
Sight Sciences	-65.90%	-45.68%	-32.27%

Institutional & Insider Ownership

55.5% of Sight Sciences shares are held by institutional investors. 1.0% of Valeritas shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Sight Sciences beats Valeritas on 5 of the 8 factors compared between the two stocks.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.